Intensity Therapeutics, Inc. (NASDAQ: INTS) reported Q2 EPS of ($1.11), $0.24 worse than the analyst estimate of ($0.87).

For earnings history and earnings-related data on Intensity Therapeutics, Inc. (INTS) click here.